Format

Send to

Choose Destination
CNS Spectr. 2007 Oct;12(10):758-62.

Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial.

Author information

1
Attention-Deficit/Hyoeractivity Disorder, Division of Child and Adolescent Psychiatry, Hospital de ClĂ­nicas de Porto Alegre at the Federal University of Rio Grande do Sul, Rio Grande do Sul, Brazil.

Abstract

INTRODUCTION:

Juvenile bipolar disorder (JBD) is a highly impairing chronic mental health condition that affects children and adolescents' overall functioning. Comorbidity with attention-deficit/hyperactivity disorder (ADHD) is extremely prevalent and may determine worse response to treatment. Few investigations have addressed the use of recent atypical antipsychotics in JBD, although several guidelines suggest their use.

METHODS:

We conducted a 6-week open trial with aripiprazole in 10 children and adolescents with JBD comorbid with ADHD to assess impact on mania and ADHD symptoms, respectively, by means of the Young Mania Rating Scale and the Swanson, Nolan and Pelham Scale, as well as on global functioning (Clinical Global Impressions-Severity), and adverse events.

RESULTS:

Significant improvement in global functioning scores (F=3.17, P=.01, effect size=0.55), manic symptoms (F=5.63, P<.01; ES=0.93), and ADHD symptoms (t=3.42, P<.01;ES=1.05) were detected. Although an overall positive tolerability was reported, significant weight gain (F=3.07, P=.05) was observed.

CONCLUSION:

Aripiprazole was effective in improving mania and ADHD symptoms, but neither JBD nor ADHD symptom remission was observed in most of the cases. Randomized placebo-controlled trials for JBD and ADHD are needed.

PMID:
17934380
DOI:
10.1017/s1092852900015443
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center